CNS Library
Library of novel small molecules with high CNS MPO scores
47 360 compounds
To create the CNS-targeted library that will enable discovery of new CNS drugs we employed versatile approaches, bearing in mind molecular properties and structural features preferable for BBB permeability.
We have carefully selected diverse compounds with desirable CNS properties. All compounds are stored as dry materials and they can be acquired in diverse custom formats. Alternatively, we can supply a copy of plated CNS Library, that can be also made in a customized ready-to-screen formats. Using our CNS Library for hit discovery you receive multiple benefits allowing you to save on time and costs in lead generation:
- Analogs and hit samples resupply from dry stock of over 4M compounds.
- Straightforward & low-cost synthesis of follow-up libraries through our REAL Database technology
- Medicinal chemistry support enhanced with on-site broad ADME/T panel
You have also an option to screen the library directly at Enamine. In this case we will be happy to offer you discount on library cost depending on the collaboration scope.
Typical Formats
Catalog No.
CNS-47-Y-0-2
Compounds
47 360
148 plates
Amount
≤150 nL of up to 10 mM DMSO solutions
Plates and formats
384-well plates Greiner Cat. No. 784201, 1, 2 & 23, 24 columns empty; 320 compounds per plate
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Catalog No.
CNS-47-Z-5-10
Compounds
47 360
37 plates
Amount
5 µL of 10 mM DMSO stock solutions
Plates and formats
1536-well plates, Labcyte Cat No. LP-0400, 1280 compounds per plate
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Catalog No.
CNS-47-Y-25-10
Compounds
47 360
148 plates
Amount
25 µL of 10 mM DMSO solutions
Plates and formats
384-well plates Greiner Cat. No. 784076, 1, 2 & 23, 24 columns empty; 320 compounds per plate
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Catalog No.
CNS-47
Compounds
47 360
Amount
Custom
Plates and formats
Any custom format
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Download SD file
Library design
Overcoming the difficulty of delivering therapeutic agents to the specific CNS sites is one of the major challenges in discovery of new treatments of neurological disorders. The criteria for selection of CNS-active molecules which are able to penetrate blood-brain barrier (BBB) were low polar surface area (TPSA < 70 Å2(median value 48 Å 2), cf.45 Å 2for the marketed CNS drugs), low degree of possible hydrogen bond formation (total number of hydrogen bond acceptors and donors are less than 8) and low ClogP values (average is 1.63). Further selection was driven by evaluation of CNS MPO desirability scores for each candidate compound.
The parameters for selection included: CNS MPO≥ 4(ClogP, ClogD, MW, TPSA, HBD, and pKa for most basic center) MW≤ 350 (median value 283, cf.305 for the marketed CNS drugs), ClogP≤ 3.0 (mean value 1.63, cf.2.8 for the marketed CNS drugs), Amide groups≤ 1, Hbond Donor≤ 2, QProp CNSvalue > 0.
Parameter
MW
Range
170 ... 350
Parameter
RotBonds
Range
≤ 4
Parameter
ClogP
Range
-0.5 ... 3.0
Parameter
Aromatic rings
Range
1 ... 3
Parameter
Hb Donors
Range
≤ 2
Parameter
Fsp 3
Range
0.15 ... 0.8
Parameter
TPSA
Range
≤ 70 Å 2
Parameter
QPPCaco-2
Range
> 500
Parameter
Amide groups
Range
≤ 1
Parameter
Basic N
Range
≤ 2
Parameter
Total H-bonding
Range
< 8
Parameter
QPlogBB
Range
-1.0-0.8
Parameter
Carboxylic acids
Range
≤ 1
Parameter
CNS
Range
> 0
Parameter
CNS MPO
Range
≥ 4
Parameter
pKa_bs
Range
-1.5 ... 8.0
Key features
Modern CNS drug discovery notions suggest that conformational constraints and rigidity of the molecules are important structural features of CNS-active compounds. Our selection of CNS compounds was enriched with recently synthesized molecules having sp 3-rich saturated ring cores of various architectures including spirocyclic (1,341 compounds, 14.5%), bridged and fused scaffolds (4,106 compounds, 44.5%).
Novelty
Compounds included into CNS focused Library were selected from all three screening collections - HTS, Advancedand Premium. Preference was given to the compounds synthesized within the last 4 years, based on innovative scaffolds and with use of advanced building blocks to enhance the novelty value of the library.
